Affinivax, Inc. clinical trials
Acquired by GlaxoSmithKline, Aug 15, 2022 · source ↗
The registry lists 2 studies whose lead sponsor is Affinivax, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 6, 2022.
- 2studies on the registry
- 0open to participants now
Before and after it joined GlaxoSmithKline
- First submitted before Affinivax, Inc. became part of GlaxoSmithKline
- 2
- First submitted after Affinivax, Inc. became part of GlaxoSmithKline
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Affinivax, Inc.’s studies test, most studies first; none is open now — 2 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 2 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed2100%
Over the years
- 220
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Affinivax, Inc.2 studies
Something wrong with this grouping? Tell us on the GlaxoSmithKline page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All GlaxoSmithKline studies →
- A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active ComparatorCompletedNCT04525599Phase 1
Sponsor listed in the registry: Affinivax, Inc. · First submitted before Affinivax, Inc. became part of GlaxoSmithKline
- Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female SubjectsCompletedNCT04265911Phase 1
Sponsor listed in the registry: Affinivax, Inc. · First submitted before Affinivax, Inc. became part of GlaxoSmithKline